This very provocative book takes the reader on a OC think-out-of-the-boxOCO journey through the development of a treatment regimen for multiple myeloma called OC dtZOCO. It is a firsthand account of how more than 50 patients with myeloma were given a non-toxic, precisely-targeted, anti-cancer treatment that was specifically adapted to their individual cancers. These Individualized Anti-Cancer Targeted Therapies (smart bombs) have produced amongst the best responses as well as survival rates for myeloma. Accordingly, the author argues that some patients might even have been OC curedOCO of their cancers. The concepts and logic behind OC dtZOCO are carefully presented in simple language so that both doctors and patients can easily understand them. Numerous tables and figures are provided, together with clear and simple explanations. This book is a valuable resource for all patients with myeloma who want to get the most out of their treatment by individualizing treatment to suit their needs, particularly for patients who have just been diagnosed with myeloma and who are taking that very important first step in their treatment. It is also a useful guide for doctors, nurses and researchers who treat and/or study myeloma.
This is a comprehensive, state-of-the-art guide to the diagnosis, treatment, and biology of multiple myeloma and related plasma disorders. Edited and written by a multidisciplinary group of recognized authorities from the Mayo Clinic, it presents clear guidelines on diagnosis and therapy and covers all aspects of multiple myeloma, from molecular classification and diagnosis, to risk stratification and therapy. Closely related plasma cell disorders such as solitary plasmacytoma, Waldenstrom macroglobulinemia, and light chain amyloidosis are discussed in detail as well. The book addresses often overlooked topics, including the role of radiation therapy, vertebral augmentation, and supportive care. Our understanding of this group of disorders is developing at an unprecedented rate, and Multiple Myeloma meets the need among oncologists and hematologists for a clear, timely, and authoritative resource on their biology, diagnosis, and treatment.
Affects primarily middle-aged and elderly patients.Recognize complications that require prompt intervention.A symptomless patient is usually not treated, whereas a symptomatic patient is actively treated.
During the past decade there has been an enormous increase in knowledge of multiple myeloma and related disorders, reflected in the publication of more than 5000 articles on the subject in scientific journals. Much of this has come about as new technologies have made it possible to refine studies on chromosomes and genes and to gain information about gene expression. It is therefore highly appropriate that this new comprehensive reference should appear at this time. The book covers the whole field of multiple myeloma, and also related diseases such as Waldemström’s macroglobulinaemia, and incorporates both the basic science underlying the diseases and their clinical management. Each chapter has been written to ’stand alone’, allowing the reader to dip into a particular subject and find information quickly without the need to browse through multiple chapters. In addition to the developments described above, all of which are considered here, many other approaches to targeted therapy are reviewed.
Multiple myeloma is the second most common hematologic malignancy, affecting 15,000 patients per year in the United States. Despite the advent of high-dose chemotherapy with stem cell transplantation, multiple myeloma remains incurable, with approximately 12,000 deaths per annum recorded in the US from the disease. Over the last 10 years, there has been a dramatic increase in our understanding of the biology of multiple myeloma, which has provided insights into mechanisms of cytotoxic resistance, both as inherent characteristics of the myeloma cell and the protective interaction between the tumor and its bone marrow microenvironment. Moreover, advances in our understanding of multiple myeloma pathogenesis have helped further define the intricacies of this complex disease. This book provides a concise overview of the state-of-the-art in multiple myeloma and should be of primary interest to clinicians as well as scientists and related caregivers alike in this rapidly changing f.
Multiple myeloma is currently still an incurable disease, but during the past decade knowledge of its molecular pathogenesis has increased rapidly. This has led to remarkable progress in both diagnosis and therapy, including in particular the approval of novel and first-in-class drugs such as thalidomide, bortezomib, and lenalidomide. This book, written by internationally acknowledged experts, covers a wide range of topics relating to multiple myeloma, including history, epidemiology, pathophysiology, clinical features, staging, and prognostic systems. The principal focus, however, is on therapy, with detailed information on the various promising treatment options which give hope that this cancer will be transformed into a chronic disease or even become curable. Individualized therapy and the variety of supportive treatment options, as described in this volume, will help in achieving this goal, as well as in reducing adverse events and improving quality of life.
Multiple myeloma is the second most prevalent hematological malignancy, with over 55,000 new cases diagnosed each year. This exciting new text, edited by lauded authorities on the topic, stands as the only available reference to assemble, review, and synthesizes the latest studies on translational therapies and clearly explains the impact of molecular pathogenesis, biology, and prognostic factors on the diagnosis, prognosis, and individualization of treatment and the development of novel therapeutic options for patients with myeloma. Moving from the bench to the bedside to the forefront of therapeutic development, this source: helps clinicians and researchers effectively deploy therapeutic strategies into clinical practice reflects trends in the use of agents which target both the tumor cell and its bone marrow microenvironment to overcome resistance to conventional therapies considers the critical role of the bone marrow microenvironment in the regulation of growth, survival, and homing of multiple myeloma discusses novel therapies in phase I and phase II trials, focusing specifically on therapeutic options for patients with newly diagnosed or relapsed/refractory multiple myeloma addresses novel therapies for other plasma cell disorders, and provides the framework for the design of next generation agents and combination therapies covers the entire scope of translational work in multiple myeloma, from advances in molecular pathogenesis, to prognostic factors, immunotherapy, and new options for newly diagnosed and relapsed multiple myeloma patients
This handbook provides up-to-date and comprehensive treatment of all plasma cell disorders, including both common and rare disorders. All disease aspects from pathogenesis to most recent therapy are covered. The text originates from the Mayo Clinic, the world's most experienced institution in plasma cell disorders. Comprehensive treatise on all plasma cell disorders from the gene level to treatment of emergencies Chapters are uniformly organized for easy data access All authors are important authorities in their field with extensive clinical experience
Multiple Myeloma and Related Serum Protein Disorders is a practical guide to the clinical use of serum and urine electrophoresis and also includes coverage of immunofixation electrophoresis. These techniques are essential in the accurate identification of monoclonal gammopathies and the diagnosis of multiple myeloma and related disorders. Interpretation is often challenging even for the experienced practitioner. Throughout the book the emphasis is on indications and practical aspects of interpreting test results. Particular attention is paid to differentiating false negative and false positive test results. The text provides clear, practical discussions extensively supported by representative images to guide the reader to accurate identification of specimens. Multiple Myeloma and Related Serum Protein Disorders serves as a practical guide for clinical pathologists as well as pathology residents, clinical laboratory scientists and medical technologists. Multiple Myeloma and Related Serum Protein Disorders Features Include: Covers both serum (blood) and urine electrophoresis Covers immunofixation electrophoresis Particular attention to differentiating false negative and false positive reports Well-illustrated throughout Concise, practical guide for practitioners and residents
Multiple myeloma is a plasma cell malignancy characterized by complex heterogenous cytogenetic abnormalities that accounts for 1.4% of all cancers, and approximately 10% of hematologic malignancies. The clinical manifestations of multiple myeloma include lytic bone lesions, cytopenia, hypercalcemia, renal dysfunction, hyperviscosity of the blood, immunodeficiency, and peripheral neuropathy. Based on the clinical and genetic data, probably all cases of multiple myeloma arise from an asymptomatic monoclonal gammopathy of unknown significance. The exact mechanism of the transition from MGUS to overt multiple myeloma is still not well understood. Recent oncogenomic studies have further advanced our understanding of the molecular pathogenesis of multiple myeloma. This book will give a comprehensive overview of the genetic and molecular epidemiology of multiple myeloma in order to get a more refined and conclusive understanding of this disease.
On March 27, 1990, the National Cancer Institute sponsored a workshop on the epidemiology of multiple myeloma, held at the National Institutes of Health. This book comprises articles prepared by participants in this work shop. Discussed in these papers are: the descriptive and analytic epidemi ology, differences in risk factors between blacks and whites, monoclonal gammopathies and their progression, and hypotheses regarding the etiology and pathogenesis of multiple myeloma. Several epidemiologic research areas received particular attention during this workshop, and are reviewed in detail in this volume. There have been striking increases in the incidence of multiple myeloma over the past thirty years, especially among older individuals and blacks, which may not be entirely explained by changes in diagnostic capabilities. Occupational and environmental exposures have been associated with an increased risk of multiple myeloma, including farming exposures, occupational exposure to petroleum and rubber processing, exposure to ionizing radiation, and asso ciations with persistent virus infections. The most striking epidemiological finding is reflected in the differences in incidence rates of multiple myeloma which are twice as high in blacks as compared with whites. Further, since 1950 the mortality rates for multiple myeloma have quadrupled in blacks while doubling for whites. Among hematopoietic malignancies, multiple myeloma is the only one with increased incidence and mortality rates among blacks. 1\vo major possibilities for explaining ethnic/racial differences in suscepti bility to multiple myeloma are genetic and environmental factors.
The book extensively discusses the science of multiple myeloma, including the epidemiology, pathophysiology, diagnosis, new diagnostic and prognostic criteria and various treatment options. It covers all the aspects of myeloma therapy such as, induction therapy, hematopoietic stem cell transplantation, treatment of relapsed/refractory cases and treatment of complications. The chapter on future directions discusses the development of novel agents and strategies. The book also includes a discussion on related disorders, including amyloidosis, Waldenstrom macroglobulinemia, plasmacytoma, MGUS, and POEMS syndrome. Relevant scientific information is integrated throughout, but the focus here is on providing practical therapeutic guidance for oncologists and hematologists treating multiple myeloma. Written by an expert with pioneer work in this field, this book contains information in a systematic and user friendly layout, supported with rich illustrations, tables, figures and, algorithms. This book useful for general internists, oncologists, hematologists residents and fellows in training.
This issue of Hematology/Oncology Clinics of North America, devoted to Multiple Myeloma, is edited by Dr. Kenneth C. Anderson. Articles in this issue include: Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma; Diagnosis and Risk Stratification in Myeloma; Treatment of Newly Diagnosed Transplant Eligible Patients; Treatment of Newly Diagnosed Transplant Ineligible Patients; Treatment of Relapsed/Refractory Myeloma; Maintenance Therapy; Novel Targeted Therapies; Novel Immune-based Therapies; Allotransplantation in Myeloma; and Waldenstrom’s Macroglobulinemia.
This book presents case histories to illustrate essential points about the mechanisms of immunity and to explain some of the immunological problems seen in the clinic. It is intended to help medical students and pre-medical students to understand the importance of basic immunological mechanisms.
Multiple Myeloma: New Insights for the Healthcare Professional / 2012 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Multiple Myeloma. The editors have built Multiple Myeloma: New Insights for the Healthcare Professional / 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Multiple Myeloma in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Multiple Myeloma: New Insights for the Healthcare Professional / 2012 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.
Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promising anticancer drug targeting the proteasome. This proteasome inhibitor induces cell stress and apoptosis in the cancer cells. While multiple mechanisms are likely to be involved, proteasome inhibition may prevent the degradation of pro-apoptotic factors, permitting activation of programmed cell death in neoplastic cells dependent upon the suppression of proapoptotic pathways. This monograph on bortezomib is a valuable source of information for researchers and clinicians from the fields of oncology and pharmacology, working either in academia or the pharmaceutical industry.
Multiple Myeloma: New Insights for the Healthcare Professional: 2013 Edition is a ScholarlyEditions™ book that delivers timely, authoritative, and comprehensive information about Diagnosis and Screening. The editors have built Multiple Myeloma: New Insights for the Healthcare Professional: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Diagnosis and Screening in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Multiple Myeloma: New Insights for the Healthcare Professional: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.
"Multiple Myeloma (MM), the second most common blood cancer in adults, is a clonal plasma cell malignancy within the bone marrow characterized by osteolytic bone lesions, renal disease, and immunodeficiency. It is now well established that MM cell- induced"
Expert physicians and clinical researchers summarize and explain all the recent advances in the biology and treatment of bone marrow-based malignancy. On the biological side, the authors show the characteristics of the malignant cell and describe the significant roles played by oncogenic changes, chromosomal anomalies, Kaposi's sarcoma herpes virus, and cytokines. New epidemiological findings and prognostic factors are also analyzed. On the clinical side, the authors provide a comprehensive review of conventional treatment regimens, as well as a discussion of newer experimental approaches involving immunologic targeting, inhibitors of drug resistance, and antitumor agents.
Despite the advances in conventional, novel agent and high dose chemotherapy multiple myeloma (MM) remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in MM focusing on the development of molecularly-based combination therapies has great promise to achieve high frequency and durable responses in the majority of patients. Two major advances are making this goal possible. First, recent advances in genomics and proteomics in MM have allowed for increased understanding of disease pathogenesis, identified novel therapeutic targets, allowed for molecular classification, and provided the scientific rationale for combining targeted therapies to increase tumor cell cytotoxicity and abrogate drug resistance. Second, there is now an increased understanding of how adhesion of MM cells in bone marrow (BM) further impacts gene expression in MM cells, as well as in BM stromal cells (BMSCs). As a result of these advances in oncogenomics on the one hand and increased understanding of the role of the BM in the pathogenesis of MM on the other, a new treatment paradigm targeting the tumor cell and its BM microenvironment to overcome drug resistance and improve patient outcome has now been developed. Thalidomide, lenalidomide, and Bortezomib are three agents which target the tumor cell in its microenvironment in both laboratory and animal models and which have rapidly translated from the bench to the bedside. Ongoing efforts are using oncogenomics and cell signaling studies to identify next generation of therapies in MM on the one hand, and to inform the design of combination trials on the other. This new paradigm for overcoming drug resistance and improving patient outcome in MM has great promise not only to change the natural history of MM, but also to serve as a model for targeted therapeutics directed to improve outcome of patients with MM.